Adjust Font Size:

Press Releases

ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction

IP Coverage for Proprietary Single-Blastomere Technology Could Facilitate Licensing Deals and Partnerships

MARLBOROUGH, Mass. — Feb. 23, 2011. Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued a patent on its “single-blastomere” technique. Patent Number 7,893,315 broadly covers ACT’s proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.

“Of the more than 150 patents and patent applications related to stem cell therapy and regenerative medicine that ACT owns or licenses, this patent on our single-blastomere technology is one of the most significant,” stated Gary Rabin, ACT’s interim chairman and CEO. “It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology. We are currently developing a collaboration for creating banks of these cells using our proprietary technique with the United Kingdom’s Roslin Cells. This is an example of the type of potentially revenue-generating future partnership that we think this IP (intellectual property) protection could help facilitate.”

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential. The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human body, including insulin-producing cells, blood cells, beating heart cells, cartilage, and other cell types of therapeutic importance. The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world. ACT’s “embryo-safe” technique has been published in been peer-reviewed journals such as Nature and Cell Stem Cell.

Robert Lanza, M.D., chief scientific officer of ACT, said, “This patent issuance represents recognition of the innovation underlying our single-blastomere technology. In the US alone, over 100 people die every hour from diseases that could potentially benefit from this ‘embryo-safe’ technique. Single cells are removed from the embryos, which remain healthy and continue to develop normally at rates consistent with whole (non-biopsied) embryos. Furthermore, this IP protection follows on the issuance of a broad patent relating to ACT’s production and therapeutic use of Retinal Pigment Epithelial (RPE) cells in 2010. We are eagerly anticipating the start of the two Phase 1/2 clinical trials in the first half of this year. Our RPE program uses hESCs derived from a single blastomere, and as such, this source of embryonic stem cells has been subjected to extensive regulatory scrutiny in order to demonstrate their safety and suitability to be used in human patients on a trial basis.”

ACT has been issued clearance from the FDA to proceed with two Phase 1/2 clinical trials in the U.S. for its RPE program, including a Phase 1/2 trial in patients with dry age-related macular degeneration.

*About Advanced Cell Technology, Inc.*
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

*Forward-Looking Statements*
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

*Contact:*

Investors:
CEOcast, Inc., James Young, 212-732-4300

Press:
ACT Corporate Communications, Bill Douglass, 646-450-3615
or:
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292

Press Contact


Bill Douglass
646-450-3615

Download PDF


ACTC_-_Release_-_Single_Blastomere_IP_-_FINAL.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat